Literature DB >> 26337658

Orphan drugs: expensive yet necessary.

H I Hyry1, J C Roos2, T M Cox2.   

Abstract

Year:  2015        PMID： 26337658      PMCID： PMC4888322          DOI： 10.1093/qjmed/hcv150

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


× No keyword cloud information.
  4 in total

1.  Limits on use of health economic assessments for rare diseases.

Authors:  H I Hyry; A D Stern; T M Cox; J C P Roos
Journal:  QJM       Date:  2014-01-22

2.  Orphan drugs: expensive yet necessary.

Authors:  H I Hyry; J C P Roos; T M Cox
Journal:  QJM       Date:  2014-11-28

3.  Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

Authors:  Hans Andersson; Paige Kaplan; Katherine Kacena; John Yee
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

4.  The legal imperative for treating rare disorders.

Authors:  Hanna I Hyry; Jonathan C P Roos; Jeremy Manuel; Timothy M Cox
Journal:  Orphanet J Rare Dis       Date:  2013-09-06       Impact factor: 4.123
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.